CELLIN

CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELL INTELLIGENCE 肿瘤细胞治疗研究

← 返回前沿论文

TIL（肿瘤浸润淋巴细胞）与乳腺放疗：国际免疫肿瘤生物标志物工作组展望

英文原题：Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

查看英文原题

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

PubMed 2026/09/01（内容时间） Lancet Oncol Q1 · IF 33.7（JCR 2025）
技术：TIL乳腺癌地区：欧洲地区：其他
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

研究概要

TIL（肿瘤浸润淋巴细胞）（TILs）是乳腺癌的预后和预测生物标志物。

中文摘要

TIL（肿瘤浸润淋巴细胞）（TILs）是乳腺癌的预后和预测生物标志物。治疗前高水平的TILs与良好的预后和对全身治疗反应的改善相关。然而，TILs在介导乳腺癌放疗反应中的作用仍未被充分探索，迄今为止临床证据稀缺。在本综述中，我们概述了当前证据和潜在机制，强调了将TILs整合到放射肿瘤学试验和临床实践中的机会，并呼吁标准化的TIL报告，以加速乳腺癌放疗的生物标志物驱动个体化。

展开英文摘要原文

Tumour-infiltrating lymphocytes (TILs) are prognostic and predictive biomarkers in breast cancer. High pre-treatment TILs are associated with a favourable prognosis and improved response to systemic therapies. However, the role of TILs in mediating response to radiotherapy in breast cancer remains underexplored, with scarce clinical evidence to date. In this Review, we present an overview of current evidence and potential mechanisms, highlight opportunities for integrating TILs into radiation oncology trials and clinical practice, and call for standardised TIL reporting to accelerate biomarker-driven individualisation of radiotherapy in breast cancer.

论文信息

作者
Gunster JLB、Tramm T、Machiels M、Demaria S、Formenti SC、de Caluwe A、Duane F、Klein J
第一作者单位
Department of Radiation Oncology, Leiden University Medical Centre, Leiden, Netherlands; Department of Radiation Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.Netherlands
通讯作者单位
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Electronic address: william.tran@sunnybrook.ca.Canada
文献类型
综述
期刊
The Lancet. Oncology2026 Sep
原文标识
PubMed 42636842　·　DOI 10.1016/S1470-2045(26)00255-X

在 PubMed 查看 → 出版商原文（DOI） 报告译文或资料问题 →